Latest Breaking News On - Ohio state university speror cataland - Page 1 : comparemela.com

The FDA announced it has approved Adzynma as prophylactic or on-demand enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura.

Peter marksSperor catalandWexner medical centerCongress spotlightOhio state universityUs thrombotic microangiopathy allianceOhio state university speror catalandDrug administrationTakeda pharmaceuticalsRare pediatric disease priority review voucherPriority reviewFast trackBiologics evaluationFirst treatmentRare inherited blood clottingPivotal phase